Skip to main content

Table 3 Factors associated with fatigue

From: PREVALENCE OF FATIGUE AND IMPACT ON QUALITY OF LIFE IN CASTRATION-RESISTANT PROSTATE CANCER PATIENTS: the VITAL study

 

Bivariate

Multivariate

OR (95% CI)

p-value

OR (95% CI)

p-value

Age

1.032 (0.995–1.071)

0.089

PSA

1.001 (0.999–1.003)

0.464

Testosterone

0.984 (0.956–1.012)

0.248

Hb

0.821 (0.666–1.012)

0.065

LDH

0.999 (0.996–1.003)

0.680

ALP

1.001 (0.998–1.005)

0.503

Albumin

0.404 (0.159–1.025)

0.056

 

Sodium

0.889 (0.782–1.010)

0.071

Alcohol consumption

2.750 (0.793–9.542)

0.111

Regular exercise

0.550 (0.294–1.031)

0.062

 

Diabetes mellitus

1.918 (0.873–4.212)

0.105

Cardiovascular disorders

4.884 (1.676–14.233)

0.004

4.7 (1.6–13.9)

0.005

Respiratory disorders

3.800 (1.113–12.969)

0.033

3.6 (1.0–12.5)

0.043

High blood pressure

1.522 (0.843–2.746)

0.163

Sleep disturbances

3.982 (0.503–31.511)

0.191

Time since diagnosis

1.054 (0.981–1.132)

0.150

 

Surgical castration

0.246 (0.53–1.131)

0.072

Chemical castration

0.000 (0.000-)

1.000

Radical prostatectomy at diagnosis

0.578 (0.273–1.225)

0.153

External radiation therapy at diagnosis

1.747 (0.792–3.851)

0.167

Duration of previous LHRH therapy

 

0.757

  

7–12 months

1.000 (0.084–11.931)

1.000

13–18 months

0.583 (0.052–6.587)

0.663

19–24 months

1.111 (0.097–12.750)

0.933

25–35 months

0.905 (0.080–10.210)

0.935

36–47 months

0.857 (0.076–9.695)

0.901

48–59 months

0.571 (0.049–6.606)

0.654

≥ 60 months

1.333 (0.131–13.586)

0.808

Urinary catheter

3.857 (0.527–28.241)

0.184

Haematuria

4.370 (0.556–34.346)

0.161

  1. CI Confidence interval, Hb Haemoglobin, LDH Lactate dehydrogenase, LHRH Luteinizing hormone-releasing hormone, OR Odds ratio, PSA Prostate-specific antigen